Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Study of Oral Lenalidomide in Low- or Intermediate-1-Risk MDS
NCT00910858Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2005
- Primary completion
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide in myelodysplastic syndrome (MDS) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Area-under-the Concentration-time Curve (AUC0-24) for Lenalidomide and Area-under-the Concentration-time Curve (AUC0-5) for Lenalidomide at Day 14. Started Jan 2005; status: completed.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00910858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00910858.